SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-024237
Filing Date
2022-05-05
Accepted
2022-05-05 16:25:37
Documents
14
Period of Report
2022-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea159425-8k_nektarthera.htm   iXBRL 8-K 25014
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2022 FINANCIAL R ea159425ex99-1_nektarthera.htm EX-99.1 68197
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2062
  Complete submission text file 0001213900-22-024237.txt   277191

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nktr-20220505.xsd EX-101.SCH 3027
5 XBRL LABEL FILE nktr-20220505_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE nktr-20220505_pre.xml EX-101.PRE 22591
8 EXTRACTED XBRL INSTANCE DOCUMENT ea159425-8k_nektarthera_htm.xml XML 3491
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 22896744
SIC: 2834 Pharmaceutical Preparations